Atea Pharmaceuticals (AVIR) Research & Development: 2020-2022
Historic Research & Development for Atea Pharmaceuticals (AVIR) over the last 3 years, with Dec 2022 value amounting to $27.5 million.
- Atea Pharmaceuticals' Research & Development fell 52.36% to $27.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was $81.9 million, marking a year-over-year decrease of 51.00%. This contributed to the annual value of $144.1 million for FY2024, which is 26.14% up from last year.
- According to the latest figures from Q4 2022, Atea Pharmaceuticals' Research & Development is $27.5 million, which was up 461.47% from $4.9 million recorded in Q3 2022.
- Over the past 5 years, Atea Pharmaceuticals' Research & Development peaked at $57.8 million during Q4 2021, and registered a low of $2.8 million during Q2 2020.
- In the last 3 years, Atea Pharmaceuticals' Research & Development had a median value of $26.6 million in 2021 and averaged $25.4 million.
- In the last 5 years, Atea Pharmaceuticals' Research & Development spiked by 1,310.95% in 2021 and then tumbled by 88.60% in 2022.
- Quarterly analysis of 3 years shows Atea Pharmaceuticals' Research & Development stood at $13.8 million in 2020, then spiked by 317.53% to $57.8 million in 2021, then tumbled by 52.36% to $27.5 million in 2022.
- Its last three reported values are $27.5 million in Q4 2022, $4.9 million for Q3 2022, and $19.9 million during Q2 2022.